Prof Sarah Tabrizi

Photo

Personal Profile

Name: Sarah Tabrizi Email: s.tabrizi@ucl.ac.uk
Title: Prof Tel: 0203 448 4053
Department: Neurodegenerative Diseases Fax: 0207 611 0129
Position: Professor of Clinical Neurology (Consultant) Address: Institute of Neurology, UCL Queen Square, London, WC1N 3BG
Research Domain: Neuroscience Web Page: Personal Web Page

Profile

Research Description

At UCL’s Institute of Neurology, Sarah leads a synergistic research programme in neurodegeneration from basic cellular mechanisms of protein misfolding (using prions as a model tool) to translational clinical research. Sarah has had a major research interest in Huntington’s disease (HD) since her PhD, and Sarah’s team is spearheading a major effort to develop and test new disease-modifying therapies for HD. Her work leading TRACK-HD, an international study to understand the neurobiology of HD, has already identified biomarkers of disease progression that track the earliest phase of the neurodegenerative disease process in clinically-well individuals who carry the HD expansion mutation and those with early disease symptoms.  Her work at the laboratory level aims to translate these approaches to patients within the next few years. Sarah also identified a key role for the innate immune system in the pathogenesis of HD that has given rise to important new avenues for research into biomarkers and disease-modifying therapies for HD.  Sarah’s research programme is translating HD research directly from the lab to patients with a programme that is ultimately aimed at preventing the neurodegenerative disease process itself.


Research Activities

Cellular mechanisms underlying neurodegeneration

Neurodegeneration

Education Description

Sarah teaches on the MSc Clinical Neuroscience course, MSc advanced Neuro Imaging course and the MSc Clinical Neurology course at the UCL Institute of Neurology. She also teaches on the MSc in Neuro-Science at UCL. She regularly teaches on the Expert teaching Short Courses run by the UCL, Institute of Neurology; and the Federation of European Neuroscience teaching courses. Sarah also teaches on the BSc course in Molecular Medicine at KCL. At UCLH Trust, she teaches undergraduate and postgraduate medical trainees on Neuroscience, Neurogenetics and Neurology. Her main teaching areas are in Neurogenetics, Huntingtons disease, Prion biology, and other inherited Neurodegenerative disorders.

UCL Collaborators

Prof Parmjit Jat; Prof John Hardy; Prof Ivan Gout; Prof John Collinge; Dr Peter-Christian Kloehn; Dr Stephanie Schorge; Prof Mike O'hare

External Collaborators

Publications

    2014

    • Wild EJ, Tabrizi SJ (2014). Targets for future clinical trials in Huntington's disease: What's in the pipeline?. Movement Disorders, 29(11), 1434 - 1445. doi:10.1002/mds.26007
    • Smith MR, Syed A, Lukacsovich T, Purcell J, Barbaro BA, Worthge SA, Wei SR, Pollio G, Magnoni L, Scali C, Massai L, Franceschini D, Camarri M, Gianfriddo M, Diodato E, Thomas R, Gokce O, Tabrizi S, Caricasole A, Landwehrmeyer B, Menalled L, Murphy C, Ramboz S, Carter RL, Westerberg G, Marsh JL (2014). A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease.. Hum Mol Genet, , - . doi:10.1093/hmg/ddu010
    • Abdulkadir A, Kloppel S, Ronneberger O, Tabrizi SJ (2014). Reduction of confounding effects with voxel-wise Gaussian process regression in structural MRI. Proceedings - 2014 International Workshop on Pattern Recognition in Neuroimaging, PRNI 2014, , - . doi:10.1109/PRNI.2014.6858505
    • Rezeli M, Végvári T, Laurell T, Marko-Varga G, Silajdžić E, Björkqvist M, Tabrizi SJ (2014). Inflammatory markers in Huntington's disease plasma-A robust nanoLC-MRM-MS assay development. EuPA Open Proteomics, 3, 68 - 75. doi:10.1016/j.euprot.2014.02.003
    • Andre R, Scahill RI, Haider S, Tabrizi SJ (2014). Biomarker development for Huntington's disease. Drug Discovery Today, 19(7), 972 - 979. doi:10.1016/j.drudis.2014.03.002
    • Süssmuth SD, Haider S, Landwehrmeyer GB, Farmer R, Frost C, Tripepi G, Andersen CA, Di Bacco M, Lamanna C, Diodato E, Massai L, Diamanti D, Mori E, Magnoni L, Dreyhaupt J, Schiefele K, Craufurd D, Saft C, Rudzinska M, Ryglewicz D, Orth M, Brzozy S, Baran A, Pollio G, Andre R, Tabrizi SJ, Darpo B, Westerberg G, PADDINGTON Consortium (2014). An Exploratory Double blind, Randomised Clinical Trial with Selisistat, a SirT1 Inhibitor, in Patients with Huntington's Disease.. Br J Clin Pharmacol, , - . doi:10.1111/bcp.12512
    • Rees EM, Farmer R, Cole JH, Henley SM, Sprengelmeyer R, Frost C, Scahill RI, Hobbs NZ, Tabrizi SJ (2014). Inconsistent emotion recognition deficits across stimulus modalities in Huntington׳s disease.. Neuropsychologia, , - . doi:10.1016/j.neuropsychologia.2014.09.023
    • Rees EM, Farmer R, Cole JH, Haider S, Durr A, Landwehrmeyer B, Scahill RI, Tabrizi SJ, Hobbs NZ (2014). Cerebellar abnormalities in Huntington's disease: A role in motor and psychiatric impairment?. Mov Disord, , - . doi:10.1002/mds.25984
    • Müller HP, Kassubek J, Grön G, Sprengelmeyer R, Ludolph AC, Klöppel S, Hobbs NZ, Roos RA, Duerr A, Tabrizi SJ, Orth M, Süssmuth SD, Landwehrmeyer GB (2014). Impact of the control for corrupted diffusion tensor imaging data in comparisons at the group level: an application in Huntington disease.. Biomed Eng Online, 13, 128 - . doi:10.1186/1475-925X-13-128
    • Wild EJ, Tabrizi SJ (2014). Targets for future clinical trials in Huntington's disease: What's in the pipeline?. Mov Disord, , - . doi:10.1002/mds.26007
    • Magnusson-Lind A, Davidsson M, Silajdžić E, Hansen C, McCourt AC, Tabrizi SJ, Björkqvist M (2014). Skeletal muscle atrophy in r6/2 mice - altered circulating skeletal muscle markers and gene expression profile changes.. J Huntingtons Dis, 3(1), 13 - 24. doi:10.3233/JHD-130075
    • Jones R, Stout JC, Labuschagne I, Say M, Justo D, Coleman A, Dumas EM, Hart E, Owen G, Durr A, Leavitt BR, Roos R, O'Regan A, Langbehn D, Tabrizi SJ, Frost C (2014). The Potential of Composite Cognitive Scores for Tracking Progression in Huntington's Disease.. J Huntingtons Dis, 3(2), 197 - 207. doi:10.3233/JHD-140101
    • Quinn L, Debono K, Dawes H, Rosser AE, Nemeth AH, Rickards H, Tabrizi SJ, Quarrell O, Trender-Gerhard I, Kelson MJ, Townson J, Busse M (2014). Task-Specific Training in Huntington Disease: A Randomized Controlled Feasibility Trial.. Phys Ther, , - . doi:10.2522/ptj.20140123
    • Kostro D, Abdulkadir A, Durr A, Roos R, Leavitt BR, Johnson H, Cash D, Tabrizi SJ, Scahill RI, Ronneberger O, Klöppel S, Track-HD Study (2014). Correction of inter-scanner and within-subject variance in structural MRI based automated diagnosing.. Neuroimage, , - . doi:10.1016/j.neuroimage.2014.04.057
    • Papoutsi M, Labuschagne I, Tabrizi SJ, Stout JC (2014). The cognitive burden in Huntington's disease: Pathology, phenotype, and mechanisms of compensation.. Mov Disord, 29(5), 673 - 683. doi:10.1002/mds.25864
    • Andre R, Scahill RI, Haider S, Tabrizi SJ (2014). Biomarker development for Huntington's disease.. Drug Discov Today, , - . doi:10.1016/j.drudis.2014.03.002
    • Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, Scahill RI, Leavitt BR, Stout JC, Paulsen JS, Reilmann R, Unschuld PG, Wexler A, Margolis RL, Tabrizi SJ (2014). Huntington disease: natural history, biomarkers and prospects for therapeutics.. Nat Rev Neurol, , - . doi:10.1038/nrneurol.2014.24
    • Träger U, Andre R, Lahiri N, Magnusson-Lind A, Weiss A, Grueninger S, McKinnon C, Sirinathsinghji E, Kahlon S, Pfister EL, Moser R, Hummerich H, Antoniou M, Bates GP, Luthi-Carter R, Lowdell MW, Björkqvist M, Ostroff GR, Aronin N, Tabrizi SJ (2014). HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation.. Brain, , - . doi:10.1093/brain/awt355
    • McKinnon C, Tabrizi SJ (2014). The Ubiquitin-Proteasome System in Neurodegeneration. Antioxid Redox Signal, , - . doi:10.1089/ars.2013.5802
    • Wild EJ, tabrizi S (2014). Premanifest and early Huntington’s disease. In Bates G, Tabrizi SJ, Jones L (Ed.), Huntington's Disease (pp. - ). : Oxford University Press.

    2013

    • Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout JC, Langbehn DR, TRACK-HD Investigators (2013). Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.. Lancet Neurol, 12(7), 637 - 649. doi:10.1016/S1474-4422(13)70088-7
    • Scahill RI, Hobbs NZ, Say MJ, Bechtel N, Henley SM, Hyare H, Langbehn DR, Jones R, Leavitt BR, Roos RA, Durr A, Johnson H, Lehéricy S, Craufurd D, Kennard C, Hicks SL, Stout JC, Reilmann R, Tabrizi SJ, TRACK-HD investigators (2013). Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy.. Hum Brain Mapp, 34(3), 519 - 529. doi:10.1002/hbm.21449
    • Hensman Moss DJ, Poulter M, Beck J, Hehir J, Polke JM, Campbell T, Adamson G, Mudanohwo E, McColgan P, Haworth A, Wild EJ, Sweeney MG, Houlden H, Mead S, Tabrizi SJ (2013). C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies.. Neurology, , - . doi:10.1212/WNL.0000000000000061
    • Ghosh R, Tabrizi SJ (2013). Clinical Aspects of Huntington's Disease.. Curr Top Behav Neurosci, , - . doi:10.1007/7854_2013_238
    • Träger U, Tabrizi SJ (2013). Peripheral inflammation in neurodegeneration.. J Mol Med (Berl), 91(6), 673 - 681. doi:10.1007/s00109-013-1026-0
    • Evans SJW, Douglas I, Rawlins MD, Smeeth L, Wexler NS, Tabrizi SJ (2013). Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records. Journal of Neurology, Neurosurgery and Psychiatry, , - . doi:10.1136/jnnp-2012-304636
    • Holl AK, Wilkinson L, Tabrizi SJ, Painold A, Jahanshahi M (2013). Selective executive dysfunction but intact risky decision-making in early Huntington's disease.. Mov Disord, 28(8), 1104 - 1109. doi:10.1002/mds.25388
    • Beck J, Poulter M, Hensman D, Rohrer JD, Mahoney CJ, Adamson G, Campbell T, Uphill J, Borg A, Fratta P, Orrell RW, Malaspina A, Rowe J, Brown J, Hodges J, Sidle K, Polke JM, Houlden H, Schott JM, Fox NC, Rossor MN, Tabrizi SJ, Isaacs AM, Hardy J, Warren JD, Collinge J, Mead S (2013). Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population.. Am J Hum Genet, 92(3), 345 - 353. doi:10.1016/j.ajhg.2013.01.011
    • Scahill RI, Hobbs NZ, Say MJ, Henley SM, Tabrizi SJ, Bechtel N, Reilmann R, Hyare H, Langbehn DR, Johnson H, Jones R, Leavitt BR, Roos RA, Durr A, Lehéricy S, Craufurd D, Kennard C, Hicks SL, Stout JC (2013). Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy. Human Brain Mapping, 34(3), 519 - 529. doi:10.1002/hbm.21449
    • Evans SJW, Douglas I, Rawlins MD, Smeeth L, Wexler NS, Tabrizi SJ (2013). Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records. Journal of Neurology, Neurosurgery and Psychiatry, 84(10), 1156 - 1160. doi:10.1136/jnnp-2012-304636
    • Wild EJ, tabrizi (2013). Huntington’s disease look-alike syndromes. In Burn D (Ed.), Oxford Textbook of Movement Disorders (pp. - ). : Oxford University Press.
    • Crawford HE, Hobbs NZ, Keogh R, Langbehn DR, Frost C, Johnson H, Landwehrmeyer B, Reilmann R, Craufurd D, Stout JC, Durr A, Leavitt BR, Roos RA, Tabrizi SJ, Scahill RI (2013). Corpus Callosal Atrophy in Premanifest and Early Huntington's Disease.. J Huntingtons Dis, 2(4), 517 - 526. doi:10.3233/JHD-130077
    • Silajdžić E, Rezeli M, Végvári A, Lahiri N, Andre R, Magnusson-Lind A, Nambron R, Kalliolia E, Marko-Varga G, Warner TT, Laurell T, Tabrizi SJ, Björkqvist M (2013). A Critical Evaluation of Inflammatory Markers in Huntington's Disease Plasma.. J Huntingtons Dis, 2(1), 125 - 134. doi:10.3233/JHD-130049
    • Read J, Jones R, Owen G, Leavitt BR, Coleman A, Roos RA, Dumas EM, Durr A, Justo D, Say M, Stout JC, Tabrizi SJ, Craufurd D (2013). Quality of Life in Huntington's Disease: A Comparative Study Investigating the Impact for those with Pre-Manifest and Early Manifest Disease, and their Partners.. J Huntingtons Dis, 2(2), 159 - 175. doi:10.3233/JHD-130051
    • Diamanti D, Lahiri N, Tarditi A, Magnoni L, Fondelli C, Morena E, Malusa F, Pollio G, Diodato E, Tripepi G, Tabrizi SJ, Caricasole A, Mori E (2013). Reference Genes Selection for Transcriptional Profiling in Blood of HD Patients and R6/2 Mice.. J Huntingtons Dis, 2(2), 185 - 200. doi:10.3233/JHD-120042
    • Novak MJ, Seunarine KK, Gibbard CR, Hobbs NZ, Scahill RI, Clark CA, Tabrizi SJ (2013). White matter integrity in premanifest and early Huntington's disease is related to caudate loss and disease progression.. Cortex, , - . doi:10.1016/j.cortex.2013.11.009
    • Massai L, Petricca L, Magnoni L, Rovetini L, Haider S, Andre R, Tabrizi SJ, Süssmuth SD, Landwehrmeyer BG, Caricasole A, Pollio G, Bernocco S (2013). Development of an ELISA assay for the quantification of soluble huntingtin in human blood cells.. BMC Biochem, 14(1), 34 - . doi:10.1186/1471-2091-14-34
    • Müller H-P, Sprengelmeyer R, Kassubek J, Ludolph AC, Landwehrmeyer GB, Süssmuth SD, Grön G, Hobbs N, Cole J, Tabrizi SJ, Roos RAC, Duerr A (2013). Evaluating multicenter DTI data in Huntington's disease on site specific effects: An ex post facto approach. NeuroImage: Clinical, 2(1), 161 - 167. doi:10.1016/j.nicl.2012.12.005
    • Hobbs NZ, Cole JH, Rees EM, Crawford HE, Malone IB, Scahill RI, Tabrizi SJ, Farmer RE, Frost C, Roos RAC, Sprengelmeyer R, Landwehrmeyer B, Durr A (2013). Evaluation of multi-modal, multi-site neuroimaging measures in Huntington's disease: Baseline results from the PADDINGTON study. NeuroImage: Clinical, 2(1), 204 - 211. doi:10.1016/j.nicl.2012.12.001
    • Sprengelmeyer R, Orth M, Müller HP, Wolf RC, Grön G, Depping MS, Kassubek J, Justo D, Rees EM, Haider S, Cole JH, Hobbs NZ, Roos RA, Dürr A, Tabrizi SJ, Süssmuth SD, Landwehrmeyer GB (2013). The neuroanatomy of subthreshold depressive symptoms in Huntington's disease: a combined diffusion tensor imaging (DTI) and voxel-based morphometry (VBM) study.. Psychol Med, , 1 - 12. doi:10.1017/S003329171300247X
    • Borowsky B, Warner J, Leavitt BR, Tabrizi SJ, Roos RA, Durr A, Becker C, Sampaio C, Tobin AJ, Schulman H (2013). 8OHdG is not a biomarker for Huntington disease state or progression.. Neurology, 80(21), 1934 - 1941. doi:10.1212/WNL.0b013e318293e1a1
    • Douglas I, Evans S, Rawlins MD, Smeeth L, Tabrizi SJ, Wexler NS (2013). Juvenile Huntington's disease: a population-based study using the General Practice Research Database.. BMJ Open, 3(4), - . doi:10.1136/bmjopen-2012-002085
    • Scheller E, Abdulkadir A, Peter J, Tabrizi SJ, Frackowiak RS, Klöppel S (2013). Interregional compensatory mechanisms of motor functioning in progressing preclinical neurodegeneration.. Neuroimage, 75, 146 - 154. doi:10.1016/j.neuroimage.2013.02.058
    • Georgiou-Karistianis N, Scahill R, Tabrizi SJ, Squitieri F, Aylward E (2013). Structural MRI in Huntington's disease and recommendations for its potential use in clinical trials.. Neurosci Biobehav Rev, 37(3), 480 - 490. doi:10.1016/j.neubiorev.2013.01.022
    • van den Bogaard SJ, Dumas EM, Hart EP, Milles J, Reilmann R, Stout JC, Craufurd D, Gibbard CR, Tabrizi SJ, van Buchem MA, van der Grond J, Roos RA (2013). Magnetization transfer imaging in premanifest and manifest huntington disease: a 2-year follow-up.. AJNR Am J Neuroradiol, 34(2), 317 - 322. doi:10.3174/ajnr.A3303
    • Labuschagne I, Jones R, Callaghan J, Whitehead D, Dumas EM, Say MJ, Hart EP, Justo D, Coleman A, Dar Santos RC, Frost C, Craufurd D, Tabrizi SJ, Stout JC, TRACK-HD Investigators (2013). Emotional face recognition deficits and medication effects in pre-manifest through stage-II Huntington's disease.. Psychiatry Res, 207(1-2), 118 - 126. doi:10.1016/j.psychres.2012.09.022
    • Delmaire C, Dumas EM, Sharman MA, van den Bogaard SJ, Valabregue R, Jauffret C, Justo D, Reilmann R, Stout JC, Craufurd D, Tabrizi SJ, Roos RA, Durr A, Lehéricy S (2013). The structural correlates of functional deficits in early huntington's disease.. Hum Brain Mapp, 34(9), 2141 - 2153. doi:10.1002/hbm.22055
    • Goold R, McKinnon C, Rabbanian S, Collinge J, Schiavo G, Tabrizi S (2013). Alternative fates of newly formed PrPSc upon prion conversion on the plasma membrane.. J Cell Sci, , - . doi:10.1242/jcs.120477

    2012

    • Quarrell OW, Handley O, O'Donovan K, Dumoulin C, Ramos-Arroyo M, Biunno I, Bauer P, Kline M, Landwehrmeyer GB, Network EHD (2012). Discrepancies in reporting the CAG repeat lengths for Huntington's disease. EUROPEAN JOURNAL OF HUMAN GENETICS, 20(1), 20 - 26. doi:10.1038/ejhg.2011.136
    • Dumas EM, van den Bogaard SJ, Ruber ME, Reilman RR, Stout JC, Craufurd D, Hicks SL, Kennard C, Tabrizi SJ, van Buchem MA, van der Grond J, Roos RA (2012). Early changes in white matter pathways of the sensorimotor cortex in premanifest Huntington's disease.. Hum Brain Mapp, 33(1), 203 - 212. doi:10.1002/hbm.21205
    • Holl AK, Wilkinson L, Tabrizi SJ, Painold A, Jahanshahi M (2012). Probabilistic classification learning with corrective feedback is selectively impaired in early Huntington's disease--evidence for the role of the striatum in learning with feedback.. Neuropsychologia, 50(9), 2176 - 2186. doi:10.1016/j.neuropsychologia.2012.05.021
    • Novak MJ, Warren JD, Henley SM, Draganski B, Frackowiak RS, Tabrizi SJ (2012). Altered brain mechanisms of emotion processing in pre-manifest Huntington's disease.. Brain, 135(Pt 4), 1165 - 1179. doi:10.1093/brain/aws024
    • Fonteijn HM, Modat M, Clarkson MJ, Barnes J, Lehmann M, Hobbs NZ, Scahill RI, Tabrizi SJ, Ourselin S, Fox NC, Alexander DC (2012). An event-based model for disease progression and its application in familial Alzheimer's disease and Huntington's disease.. Neuroimage, 60(3), 1880 - 1889. doi:10.1016/j.neuroimage.2012.01.062
    • Wild EJ, Tabrizi SJ (2012). Huntington's disease. In Wood N (Ed.), Neurogenetics: a guide for clinicians (pp. - ). : Cambridge University Press.
    • Dumas EM, Say MJ, Jones R, Labuschagne I, O'Regan AM, Hart EP, van den Bogaard SJ, Queller S, Justo D, Coleman A, Dar Santos RC, Dürr A, Leavitt BR, Tabrizi SJ, Roos RA, Stout JC (2012). Visual Working Memory Impairment in Premanifest Gene-Carriers and Early Huntington's Disease.. J Huntingtons Dis, 1(1), 97 - 106. doi:10.3233/JHD-2012-120010
    • Scahill RI, Wild EJ, Tabrizi SJ (2012). Biomarkers for Huntington's disease: an update.. Expert Opin Med Diagn, 6(5), 371 - 375. doi:10.1517/17530059.2012.701205
    • Bouchard J, Truong J, Bouchard K, Dunkelberger D, Desrayaud S, Moussaoui S, Tabrizi SJ, Stella N, Muchowski PJ (2012). Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease.. J Neurosci, 32(50), 18259 - 18268. doi:10.1523/JNEUROSCI.4008-12.2012
    • Kwan W, Träger U, Davalos D, Chou A, Bouchard J, Andre R, Miller A, Weiss A, Giorgini F, Cheah C, Möller T, Stella N, Akassoglou K, Tabrizi SJ, Muchowski PJ (2012). Mutant huntingtin impairs immune cell migration in Huntington disease.. J Clin Invest, 122(12), 4737 - 4747. doi:10.1172/JCI64484
    • Weiss A, Träger U, Wild EJ, Grueninger S, Farmer R, Landles C, Scahill RI, Lahiri N, Haider S, Macdonald D, Frost C, Bates GP, Bilbe G, Kuhn R, Andre R, Tabrizi SJ (2012). Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression.. J Clin Invest, 122(10), 3731 - 3736. doi:10.1172/JCI64565
    • Stout JC, Jones R, Labuschagne I, O'Regan AM, Say MJ, Dumas EM, Queller S, Justo D, Santos RD, Coleman A, Hart EP, Dürr A, Leavitt BR, Roos RA, Langbehn DR, Tabrizi SJ, Frost C (2012). Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease.. J Neurol Neurosurg Psychiatry, 83(7), 687 - 694. doi:10.1136/jnnp-2011-301940
    • Andre R, Wild EJ, Tabrizi SJ (2012). Huntington's disease: fighting on many fronts.. Brain, 135(Pt 4), 998 - 1001. doi:10.1093/brain/aws060
    • Andre R, Tabrizi SJ (2012). Misfolded PrP and a novel mechanism of proteasome inhibition.. Prion, 6(1), 32 - 36. doi:10.4161/pri.6.1.18272
    • Kwan W, Magnusson A, Chou A, Adame A, Carson MJ, Kohsaka S, Masliah E, Möller T, Ransohoff R, Tabrizi SJ, Björkqvist M, Muchowski PJ (2012). Bone marrow transplantation confers modest benefits in mouse models of Huntington's disease.. J Neurosci, 32(1), 133 - 142. doi:10.1523/JNEUROSCI.4846-11.2012
    • Olsson MG, Davidsson S, Muhammad ZD, Lahiri N, Tabrizi SJ, Akerstrom B, Bjorkqvist M (2012). Increased levels of hemoglobin and alpha1-microglobulin in Huntington's disease.. Front Biosci (Elite Ed), 4, 950 - 957.
    • Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, Jones R, Johnson H, Craufurd D, Hicks SL, Kennard C, Landwehrmeyer B, Stout JC, Borowsky B, Scahill RI, Frost C, Langbehn DR, TRACK-HD investigators (2012). Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.. Lancet Neurol, 11(1), 42 - 53. doi:10.1016/S1474-4422(11)70263-0
    • Henley SM, Novak MJ, Frost C, King J, Tabrizi SJ, Warren JD (2012). Emotion recognition in Huntington's disease: a systematic review.. Neurosci Biobehav Rev, 36(1), 237 - 253. doi:10.1016/j.neubiorev.2011.06.002
    • Mead S, Beck J, Poulter M, Rohrer J, Adamson G, Hensman D, Polke J, Campbell T, Uphill J, Borg A, Tabrizi S, Isaacs A, Hardy J, Warren J, Collinge J (2012). Large C9ORF72 hexanucleotide expansions arise spontaneously in the healthy population but can be distinguished from pathogenic mutations by Sothern Blotting.

    2011

    • Wild E, Tabrizi SJ (2011). Huntington’s disease look-alike syndromes. In Burn D (Ed.), Oxford Textbooks in Clinical Neurology: Movement Disorders (pp. - ). : Oxford University Press.
    • Politis M, Pavese N, Tai YF, Kiferle L, Mason SL, Brooks DJ, Tabrizi SJ, Barker RA, Piccini P (2011). Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study.. Hum Brain Mapp, 32(2), 258 - 270. doi:10.1002/hbm.21008
    • Gasser T, Schöls L, Finsterer J, Baets J, De Jonghe P, Van Broeckhoven C, Di Donato S, Fontaine B, Lossos A, Lynch T, Mariotti C, Spinazzola A, Zeviani M, Szolnoki Z, Tabrizi SJ, Tallaksen CME, Harbo HF, Burgunder J-M (2011). Molecular Diagnosis of Ataxias and Spastic Paraplegias. European Handbook of Neurological Management, 2, 73 - 85. doi:10.1002/9781444346268.ch6
    • Burgunder J-M, Finsterer J, Szolnoki Z, Fontaine B, Baets J, De Jonghe P, Van Broeckhoven C, Di Donato S, Lynch T, Mariotti C, Schöls L, Spinazzola A, Zeviani M, Tabrizi SJ, Tallaksen C, Harbo HF, Gasser T (2011). Molecular Diagnosis of Channelopathies, Epilepsies, Migraine, Stroke and Dementias. European Handbook of Neurological Management, 2, 87 - 96. doi:10.1002/9781444346268.ch7
    • Novak MJ, Tabrizi SJ (2011). A man with deteriorating ability to live independently.. BMJ, 343, d7463 - .
    • Deriziotis P, André R, Smith DM, Goold R, Kinghorn KJ, Kristiansen M, Nathan JA, Rosenzweig R, Krutauz D, Glickman MH, Collinge J, Goldberg AL, Tabrizi SJ (2011). Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition of substrate entry.. EMBO J, 30(15), 3065 - 3077. doi:10.1038/emboj.2011.224
    • Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, Stout JC, TRACK-HD Investigators (2011). Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis.. Lancet Neurol, 10(1), 31 - 42. doi:10.1016/S1474-4422(10)70276-3
    • Burgunder JM, Schöls L, Baets J, Andersen P, Gasser T, Szolnoki Z, Fontaine B, Van Broeckhoven C, Di Donato S, De Jonghe P, Lynch T, Mariotti C, Spinazzola A, Tabrizi SJ, Tallaksen C, Zeviani M, Harbo HF, Finsterer J, EFNS (2011). EFNS guidelines for the molecular diagnosis of neurogenetic disorders: motoneuron, peripheral nerve and muscle disorders.. Eur J Neurol, 18(2), 207 - 217. doi:10.1111/j.1468-1331.2010.03069.x
    • Harbo HF, Tallaksen C, Finsterer J, Baets J, De Jonghe P, Van Broeckhoven C, Di Donato S, Mariotti C, Spinazzola A, Zeviani M, Fontaine B, Lossos A, Lynch T, Schöls L, Gasser T, Szolnoki Z, Tabrizi SJ, Burgunder J-M (2011). Molecular Diagnosis of Neurogenetic Disorders: General Issues, Huntington's Disease, Parkinson's Disease and Dystonias. European Handbook of Neurological Management, 2, 51 - 60. doi:10.1002/9781444346268.ch4
    • Burgunder J-M, Schöls L, Baets J, De Jonghe P, Van Broeckhoven C, Andersen P, Gasser T, Szolnoki Z, Fontaine B, Di Donato S, Lynch T, Mariotti C, Spinazzola A, Tabrizi SJ, Harbo HF, Tallaksen C, Zeviani M, Finsterer J (2011). Molecular Diagnosis of Neurogenetic Disorders: Motoneuron, Peripheral Nerve and Muscle Disorders. European Handbook of Neurological Management, 2, 97 - 109. doi:10.1002/9781444346268.ch8
    • Novak MJ, Tabrizi SJ (2011). A man with deteriorating ability to live independently.. BMJ (Clinical research ed.), 343, - .
    • Orth M, European Huntington's Disease Network , Handley OJ, Schwenke C, Dunnett S, Wild EJ, Tabrizi SJ, Landwehrmeyer GB (2011). Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY.. J Neurol Neurosurg Psychiatry, 82(12), 1409 - 1412. doi:10.1136/jnnp.2010.209668
    • Müller HP, Süssmuth SD, Landwehrmeyer GB, Ludolph A, Tabrizi SJ, Kloppel S, Kassubek J (2011). Stability effects on results of diffusion tensor imaging analysis by reduction of the number of gradient directions due to motion artifacts: an application to presymptomatic Huntington's disease.. PLoS Curr, 3, RRN1292 - . doi:10.1371/currents.RRN1292
    • Saft C, Epplen JT, Wieczorek S, Landwehrmeyer GB, Roos RA, de Yebenes JG, Dose M, Tabrizi SJ, Craufurd D, REGISTRY Investigators of the European Huntington's Disease Network , Arning L (2011). NMDA receptor gene variations as modifiers in Huntington disease: a replication study.. PLoS Curr, 3, RRN1247 - . doi:10.1371/currents.RRN1247
    • Novak MJ, Tabrizi SJ (2011). Huntington's disease: clinical presentation and treatment.. Int Rev Neurobiol, 98, 297 - 323. doi:10.1016/B978-0-12-381328-2.00013-4
    • Zuccato C, Marullo M, Vitali B, Tarditi A, Mariotti C, Valenza M, Lahiri N, Wild EJ, Sassone J, Ciammola A, Bachoud-Lèvi AC, Tabrizi SJ, Di Donato S, Cattaneo E (2011). Brain-derived neurotrophic factor in patients with Huntington's disease.. PLoS One, 6(8), e22966 - . doi:10.1371/journal.pone.0022966
    • Wild E, Magnusson A, Lahiri N, Krus U, Orth M, Tabrizi SJ, Björkqvist M (2011). Abnormal peripheral chemokine profile in Huntington's disease.. PLoS Curr, 3, RRN1231 - . doi:10.1371/currents.RRN1231
    • Müller HP, Glauche V, Novak MJ, Nguyen-Thanh T, Unrath A, Lahiri N, Read J, Say MJ, Tabrizi SJ, Kassubek J, Kloppel S (2011). Stability of white matter changes related to Huntington's disease in the presence of imaging noise: a DTI study.. PLoS Curr, 3, RRN1232 - . doi:10.1371/currents.RRN1232
    • Hobbs NZ, Pedrick AV, Say MJ, Frost C, Dar Santos R, Coleman A, Sturrock A, Craufurd D, Stout JC, Leavitt BR, Barnes J, Tabrizi SJ, Scahill RI (2011). The structural involvement of the cingulate cortex in premanifest and early Huntington's disease.. Mov Disord, 26(9), 1684 - 1690. doi:10.1002/mds.23747
    • Goold R, Rabbanian S, Sutton L, Andre R, Arora P, Moonga J, Clarke AR, Schiavo G, Jat P, Collinge J, Tabrizi SJ (2011). Rapid cell-surface prion protein conversion revealed using a novel cell system.. Nat Commun, 2, 281 - . doi:10.1038/ncomms1282
    • Gaughwin PM, Ciesla M, Lahiri N, Tabrizi SJ, Brundin P, Björkqvist M (2011). Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease.. Hum Mol Genet, 20(11), 2225 - 2237. doi:10.1093/hmg/ddr111
    • Munsie L, Caron N, Atwal RS, Marsden I, Wild EJ, Bamburg JR, Tabrizi SJ, Truant R (2011). Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease.. Hum Mol Genet, 20(10), 1937 - 1951. doi:10.1093/hmg/ddr075
    • Ross CA, Tabrizi SJ (2011). Huntington's disease: from molecular pathogenesis to clinical treatment.. Lancet Neurol, 10(1), 83 - 98. doi:10.1016/S1474-4422(10)70245-3
    • Say MJ, Jones R, Scahill RI, Dumas EM, Coleman A, Santos RC, Justo D, Campbell JC, Queller S, Shores EA, Tabrizi SJ, Stout JC, TRACK-HD Investigators (2011). Visuomotor integration deficits precede clinical onset in Huntington's disease.. Neuropsychologia, 49(2), 264 - 270. doi:10.1016/j.neuropsychologia.2010.11.016
    • van den Bogaard SJ, Dumas EM, Acharya TP, Johnson H, Langbehn DR, Scahill RI, Tabrizi SJ, van Buchem MA, van der Grond J, Roos RA, TRACK-HD Investigator Group (2011). Early atrophy of pallidum and accumbens nucleus in Huntington's disease.. J Neurol, 258(3), 412 - 420. doi:10.1007/s00415-010-5768-0
    • Finsterer J, Tallaksen C, Harbo HF, Baets J, De Jonghe P, Van Broeckhoven C, Di Donato S, Mariotti C, Spinazzola A, Zeviani M, Fontaine B, Lossos A, Lynch T, Schöls L, Gasser T, Szolnoki Z, Tabrizi SJ, Burgunder J-M (2011). Molecular Diagnosis of Mitochondrial Disorders. European Handbook of Neurological Management, 2, 61 - 72. doi:10.1002/9781444346268.ch5

    2010

    • Ahmed Z, Tabrizi S, Li A, Houlden H, Sailer A, Lees AJ, Revesz T, Holton JL (2010). A case of Huntington's disease phenocopy characterised by pallido-nigro-luysian degeneration with brain-iron accumulation and p62-positive glial inclusions.
    • Lahiri N, Tabrizi SJ, Kennard C, Durr A, Leavitt BR, Fox N, Roos RA (2010). POMD07 Quantitative assessment of biological and clinical manifestations of Huntington's disease before and after diagnosis--the TRACK-HD study.. J Neurol Neurosurg Psychiatry, 81(11), e59 - . doi:10.1136/jnnp.2010.226340.167
    • Ahmed Z, Tabrizi SJ, Li A, Houlden H, Sailer A, Lees AJ, Revesz T, Holton JL (2010). A Huntington's disease phenocopy characterized by pallido-nigro-luysian degeneration with brain iron accumulation and p62-positive glial inclusions.. Neuropathol Appl Neurobiol, 36(6), 551 - 557. doi:10.1111/j.1365-2990.2010.01093.x
    • Henley SM, Ridgway GR, Scahill RI, Klöppel S, Tabrizi SJ, Fox NC, Kassubek J, EHDN Imaging Working Group (2010). Pitfalls in the use of voxel-based morphometry as a biomarker: examples from huntington disease.. AJNR Am J Neuroradiol, 31(4), 711 - 719. doi:10.3174/ajnr.A1939
    • Burgunder JM, Finsterer J, Szolnoki Z, Fontaine B, Baets J, Van Broeckhoven C, Di Donato S, De Jonghe P, Lynch T, Mariotti C, Schöls L, Spinazzola A, Tabrizi SJ, Tallaksen C, Zeviani M, Harbo HF, Gasser T, EFNS (2010). EFNS guidelines on the molecular diagnosis of channelopathies, epilepsies, migraine, stroke, and dementias.. Eur J Neurol, 17(5), 641 - 648. doi:10.1111/j.1468-1331.2010.02985.x
    • Novak MJ, Tabrizi SJ (2010). Huntington's disease.. BMJ, 340, c3109 - .
    • Schneider SA, Wilkinson L, Bhatia KP, Henley SM, Rothwell JC, Tabrizi SJ, Jahanshahi M (2010). Abnormal explicit but normal implicit sequence learning in premanifest and early Huntington's disease.. Mov Disord, 25(10), 1343 - 1349. doi:10.1002/mds.22692
    • Lahiri N, Mead S, Tabrizi SJ (2010). Chorea in prion diseases. In Walker RH (Ed.), The Differential Diagnosis of Chorea (pp. - ). : Oxford University Press.
    • Hobbs NZ, Barnes J, Frost C, Henley SM, Wild EJ, Macdonald K, Barker RA, Scahill RI, Fox NC, Tabrizi SJ (2010). Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study.. AJNR Am J Neuroradiol, 31(6), 1036 - 1041. doi:10.3174/ajnr.A2018
    • Gasser T, Finsterer J, Baets J, Van Broeckhoven C, Di Donato S, Fontaine B, De Jonghe P, Lossos A, Lynch T, Mariotti C, Schöls L, Spinazzola A, Szolnoki Z, Tabrizi SJ, Tallaksen CM, Zeviani M, Burgunder JM, Harbo HF, EFNS (2010). EFNS guidelines on the molecular diagnosis of ataxias and spastic paraplegias.. Eur J Neurol, 17(2), 179 - 188. doi:10.1111/j.1468-1331.2009.02873.x
    • Marullo M, Zuccato C, Mariotti C, Lahiri N, Tabrizi SJ, Di Donato S, Cattaneo E (2010). Expressed Alu repeats as a novel, reliable tool for normalization of real-time quantitative RT-PCR data.. Genome Biol, 11(1), R9 - . doi:10.1186/gb-2010-11-1-r9
    • Dubinsky R, Roberson J, Battaglia G, Cannella M, Riozzi B, Orobello S, Maat-Schieman ML, Aronica E, Busceti CL, Ciarmiello A, Alberti S, Sassone J, Sipione S, Bruno V, Frati L, Nicoletti F, Squitieri F, Rao A, Gordon A, Marder K, Nolta J, Anderson K, Gruber-Baldini A, Medalie J, Reich S, Fishman P, Robottom B, Weiner W, Shulman L, Langbehn D, Paulsen J, PREDICT-HD Investigators of the Huntington Study Group , Witten C, Cox M, Feigin A, Napolitano B, Goh A, Yastrubetskaya O, Chiu E, Cloud L, Helmers S, Jones R, Factor S, Emory CT, Kegelmeyer D, Kostyk S, Fritz N, Kloos A, Lessig S, Goldstein J, Corey-Bloom J, Simonelli M, Martino T, Colonnese C, Callaghan J, Arran N, Boisse MF, Coleman A, Dar Santos R, Dumas E, Hart E, Justo D, Read J, Say M, Van Den Bogaard S, Durr A, Leavitt B, Roos R, Tabrizi S, Bourdet C, van Duijn E, Craufurd D, TRACK-FID Investigators , Evans K, Vaccarino A, TRACK-HD Investigators , Aylward E, Nopoulos P, Ross C, Pierson R, Mills J, Magnotta V, Johnson H, PREDICT-HD Investigators and Coordinators of the Huntington Study Group , Mitchell A, Cortes JC, Dahmubed A, Krakauer J, Mazzoni P, Russell D, Jennings D, Tamagnan G, Seibyl J, Koren A, Zubal G, Marek K, Goodman L, Carnes R, Giuliano J, Vetter L, Macdonald M, Lee JM, Seong IS, Fossale E, Anderson MA, Wheeler V, Gusella J, Johnson J, Yu T, Jones D, Chan A, Richardson K, McCusker E, Loy C, Griffith J, Paulsen JS, PREDICT-HD Investigators of the Huntington Study Group , Waters S, Tedroff J, Kieburtz K, Krogh PL, Buusman A, Rembratt A, Dorey J, Lamure M, Toumi M, von der Schulenburg JM, Pettersson F, Dyhring T, Sonesson C, Waters N, Pontén H, Erwin C, Williams J, Juhl A, Investigators of the Huntington Study Group , Huntington Study Group PHAROS Investigators , Adams W, Byars J, O'Rourke J, Flynn A, Fiedorowicz J, Duff K, Leserman A, Beglinger L, Smith M, Stout J, Queller S, Rao S, Zimbelman J, Groves M, Guttman M, Wexler E, Perlman S, Burgunder JM, Rosenblatt A, van Kammen D, PREDICT-HD Investigators of the Huntington Study Group (2010). Third annual huntington disease clinical research symposium : organized by the huntington study group.. Neurotherapeutics, 7(1), 135 - 147. doi:10.1007/BF03215660
    • Bechtel N, Scahill RI, Rosas HD, Acharya T, van den Bogaard SJ, Jauffret C, Say MJ, Sturrock A, Johnson H, Onorato CE, Salat DH, Durr A, Leavitt BR, Roos RA, Landwehrmeyer GB, Langbehn DR, Stout JC, Tabrizi SJ, Reilmann R (2010). Tapping linked to function and structure in premanifest and symptomatic Huntington disease.. Neurology, 75(24), 2150 - 2160. doi:10.1212/WNL.0b013e3182020123
    • Sturrock A, Laule C, Decolongon J, Dar Santos R, Coleman AJ, Creighton S, Bechtel N, Reilmann R, Hayden MR, Tabrizi SJ, Mackay AL, Leavitt BR (2010). Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease.. Neurology, 75(19), 1702 - 1710. doi:10.1212/WNL.0b013e3181fc27e4
    • Hicks S, Rosas HD, Berna C, Scahill R, Durmas E, Roos RA, Levitt B, Tabrizi SJ, Kennard C, Durr A (2010). PAW36 Oculomotor deficits in presymptomatic and early Huntington's disease and their structural brain correlates.. J Neurol Neurosurg Psychiatry, 81(11), e33 - . doi:10.1136/jnnp.2010.226340.64
    • Novak MJ, Sweeney MG, Li A, Treacy C, Chandrashekar HS, Giunti P, Goold RG, Davis MB, Houlden H, Tabrizi SJ (2010). An ITPR1 gene deletion causes spinocerebellar ataxia 15/16: a genetic, clinical and radiological description.. Mov Disord, 25(13), 2176 - 2182. doi:10.1002/mds.23223
    • Novak MJ, TABRIZI S (2010). Huntington’s disease. In (Ed.), (pp. c3109 - ). : . doi:10.1136/bmj.c3109
    • Klöppel S, Stonnington CM, Petrovic P, Mobbs D, Tüscher O, Craufurd D, Tabrizi SJ, Frackowiak RS (2010). Irritability in pre-clinical Huntington's disease.. Neuropsychologia, 48(2), 549 - 557. doi:10.1016/j.neuropsychologia.2009.10.016
    • Orth M, Handley OJ, Schwenke C, Dunnett SB, Craufurd D, Ho AK, Wild E, Tabrizi SJ, Landwehrmeyer GB, Investigators of the European Huntington's Disease Network (2010). Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRY.. PLoS Curr, 2, RRN1184 - . doi:10.1371/currents.RRN1184
    • Pavese N, Politis M, Tai YF, Barker RA, Tabrizi SJ, Mason SL, Brooks DJ, Piccini P (2010). Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers.. Neurobiol Dis, 37(2), 356 - 361. doi:10.1016/j.nbd.2009.10.015
    • Orth M, Schippling S, Schneider SA, Bhatia KP, Talelli P, Tabrizi SJ, Rothwell JC (2010). Abnormal motor cortex plasticity in premanifest and very early manifest Huntington disease.. J Neurol Neurosurg Psychiatry, 81(3), 267 - 270. doi:10.1136/jnnp.2009.171926
    • Hobbs NZ, Henley SM, Ridgway GR, Wild EJ, Barker RA, Scahill RI, Barnes J, Fox NC, Tabrizi SJ (2010). The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study.. J Neurol Neurosurg Psychiatry, 81(7), 756 - 763. doi:10.1136/jnnp.2009.190702
    • Wild EJ, Henley SM, Hobbs NZ, Frost C, MacManus DG, Barker RA, Fox NC, Tabrizi SJ (2010). Rate and acceleration of whole-brain atrophy in premanifest and early Huntington's disease.. Mov Disord, 25(7), 888 - 895. doi:10.1002/mds.22969

    2009

    • Lahiri N, Tabrizi SJ (2009). Huntington disease: a tale of two genes.. Neurology, 73(16), 1254 - 1255. doi:10.1212/WNL.0b013e3181beed15
    • Mead S, Poulter M, Uphill J, Beck J, Whitfield J, Webb TE, Campbell T, Adamson G, Deriziotis P, Tabrizi SJ, Hummerich H, Verzilli C, Alpers MP, Whittaker JC, Collinge J (2009). Genetic risk factors for variant Creutzfeldt-Jakob disease: a genome-wide association study.. Lancet Neurol, 8(1), 57 - 66. doi:10.1016/S1474-4422(08)70265-5
    • Klöppel S, Henley SM, Hobbs NZ, Wolf RC, Kassubek J, Tabrizi SJ, Frackowiak RS (2009). Magnetic resonance imaging of Huntington's disease: preparing for clinical trials.. Neuroscience, 164(1), 205 - 219. doi:10.1016/j.neuroscience.2009.01.045
    • Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, Landwehrmeyer B, Stout JC, TRACK-HD investigators (2009). Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.. Lancet Neurol, 8(9), 791 - 801. doi:10.1016/S1474-4422(09)70170-X
    • Henley SM, Wild EJ, Hobbs NZ, Frost C, MacManus DG, Barker RA, Fox NC, Tabrizi SJ (2009). Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease.. Mov Disord, 24(6), 932 - 936. doi:10.1002/mds.22485
    • Klöppel S, Chu C, Tan GC, Draganski B, Johnson H, Paulsen JS, Kienzle W, Tabrizi SJ, Ashburner J, Frackowiak RS, PREDICT-HD Investigators of the Huntington Study Group (2009). Automatic detection of preclinical neurodegeneration: presymptomatic Huntington disease.. Neurology, 72(5), 426 - 431. doi:10.1212/01.wnl.0000341768.28646.b6
    • Henley SM, Wild EJ, Hobbs NZ, Scahill RI, Ridgway GR, Macmanus DG, Barker RA, Fox NC, Tabrizi SJ (2009). Relationship between CAG repeat length and brain volume in premanifest and early Huntington's disease.. J Neurol, 256(2), 203 - 212. doi:10.1007/s00415-009-0052-x
    • Quinn N, Bhatia K, Brown P, Cordivari C, Hariz M, Lees A, Limousin P, Robertson M, Schrag A, Tabrizi S (2009). Movement disorders. In Clarke C, Howard R, Rossor M, Shorvon S (Ed.), Neurology: a Queen Square textbook (pp. 155 - 187). : Wiley-Blackwell.
    • Schneider SA, Wilkinson L, Bhatia KP, Henley S, Rothwell J, Tabrizi SJ, Jahanshahi M (2009). Abnormal explicit but intact implicit sequence learning in presymptomatic and early Huntington's disease. MOVEMENT DISORDERS, 24, S169 - S169.
    • Gandhi S, Tabrizi SJ, Wood NW (2009). Neurogenetics. In Scadding J, Losseff N (Ed.), Clinical Neurology (pp. - ). : Hodder Arnold.
    • Björkqvist M, Wild EJ, Tabrizi SJ (2009). Harnessing immune alterations in neurodegenerative diseases.. Neuron, 64(1), 21 - 24. doi:10.1016/j.neuron.2009.09.034
    • Hobbs NZ, Henley SM, Wild EJ, Leung KK, Frost C, Barker RA, Scahill RI, Barnes J, Tabrizi SJ, Fox NC (2009). Automated quantification of caudate atrophy by local registration of serial MRI: evaluation and application in Huntington's disease.. Neuroimage, 47(4), 1659 - 1665. doi:10.1016/j.neuroimage.2009.06.003
    • Harbo HF, Finsterer J, Baets J, Van Broeckhoven C, Di Donato S, Fontaine B, De Jonghe P, Lossos A, Lynch T, Mariotti C, Schöls L, Spinazzola A, Szolnoki Z, Tabrizi SJ, Tallaksen C, Zeviani M, Burgunder JM, Gasser T, EFNS (2009). EFNS guidelines on the molecular diagnosis of neurogenetic disorders: general issues, Huntington's disease, Parkinson's disease and dystonias.. Eur J Neurol, 16(7), 777 - 785. doi:10.1111/j.1468-1331.2009.02646.x
    • Schippling S, Schneider SA, Bhatia KP, Münchau A, Rothwell JC, Tabrizi SJ, Orth M (2009). Abnormal motor cortex excitability in preclinical and very early Huntington's disease.. Biol Psychiatry, 65(11), 959 - 965. doi:10.1016/j.biopsych.2008.12.026
    • Klöppel S, Draganski B, Siebner HR, Tabrizi SJ, Weiller C, Frackowiak RS (2009). Functional compensation of motor function in pre-symptomatic Huntington's disease.. Brain, 132(Pt 6), 1624 - 1632. doi:10.1093/brain/awp081
    • Robert MP, Nachev PC, Hicks SL, Golding CV, Tabrizi SJ, Kennard C (2009). Saccadometry of conditional rules in presymptomatic Huntington's disease.. Ann N Y Acad Sci, 1164, 444 - 450. doi:10.1111/j.1749-6632.2008.03736.x
    • Gandhi S, Wood-Kaczmar A, Yao Z, Plun-Favreau H, Deas E, Klupsch K, Downward J, Latchman DS, Tabrizi SJ, Wood NW, Duchen MR, Abramov AY (2009). PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death.. Mol Cell, 33(5), 627 - 638. doi:10.1016/j.molcel.2009.02.013
    • Finsterer J, Harbo HF, Baets J, Van Broeckhoven C, Di Donato S, Fontaine B, De Jonghe P, Lossos A, Lynch T, Mariotti C, Schöls L, Spinazzola A, Szolnoki Z, Tabrizi SJ, Tallaksen CM, Zeviani M, Burgunder JM, Gasser T, European Federation of Neurological Sciences (2009). EFNS guidelines on the molecular diagnosis of mitochondrial disorders.. Eur J Neurol, 16(12), 1255 - 1264.

    2008

    • Klöppel S, Draganski B, Golding CV, Chu C, Nagy Z, Cook PA, Hicks SL, Kennard C, Alexander DC, Parker GJ, Tabrizi SJ, Frackowiak RS (2008). White matter connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington's disease.. Brain, 131(Pt 1), 196 - 204. doi:10.1093/brain/awm275
    • Hicks SL, Robert MP, Golding CV, Tabrizi SJ, Kennard C (2008). Oculomotor deficits indicate the progression of Huntington's disease.. Prog Brain Res, 171, 555 - 558. doi:10.1016/S0079-6123(08)00678-X
    • Wild EJ, Tabrizi SJ (2008). Biomarkers for Huntington's disease.. Expert Opin Med Diagn, 2(1), 47 - 62. doi:10.1517/17530059.2.1.47
    • Leoni V, Mariotti C, Tabrizi SJ, Valenza M, Wild EJ, Henley SM, Hobbs NZ, Mandelli ML, Grisoli M, Björkhem I, Cattaneo E, Di Donato S (2008). Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease.. Brain, 131(Pt 11), 2851 - 2859. doi:10.1093/brain/awn212
    • Tabrizi S, Craufurd D, Durr A, Fox N, Frost C, Hicks S, Illmann T, Johnson H, Kennard C, Landwehrmeyer GB, Langbehn D, Track -HD Investigat (2008). Track-HD tracking progression in premanifest and early Huntington's disease.
    • Deriziotis P, Tabrizi SJ (2008). Prions and the proteasome.. Biochim Biophys Acta, 1782(12), 713 - 722. doi:10.1016/j.bbadis.2008.06.011
    • Wild E, Björkqvist M, Tabrizi SJ (2008). Immune markers for Huntington's disease?. Expert Rev Neurother, 8(12), 1779 - 1781. doi:10.1586/14737175.8.12.1779
    • Politis M, Pavese N, Tai YF, Tabrizi SJ, Barker RA, Piccini P (2008). Hypothalamic involvement in Huntington's disease: an in vivo PET study.. Brain, 131(Pt 11), 2860 - 2869. doi:10.1093/brain/awn244
    • Björkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, Raibon E, Lee RV, Benn CL, Soulet D, Magnusson A, Woodman B, Landles C, Pouladi MA, Hayden MR, Khalili-Shirazi A, Lowdell MW, Brundin P, Bates GP, Leavitt BR, Möller T, Tabrizi SJ (2008). A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease.. J Exp Med, 205(8), 1869 - 1877. doi:10.1084/jem.20080178
    • Henley SM, Wild EJ, Hobbs NZ, Warren JD, Frost C, Scahill RI, Ridgway GR, MacManus DG, Barker RA, Fox NC, Tabrizi SJ (2008). Defective emotion recognition in early HD is neuropsychologically and anatomically generic.. Neuropsychologia, 46(8), 2152 - 2160. doi:10.1016/j.neuropsychologia.2008.02.025
    • Wood-Kaczmar A, Gandhi S, Yao Z, Abramov AY, Miljan EA, Keen G, Stanyer L, Hargreaves I, Klupsch K, Deas E, Downward J, Mansfield L, Jat P, Taylor J, Heales S, Duchen MR, Latchman D, Tabrizi SJ, Wood NW (2008). PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons.. PLoS One, 3(6), e2455 - . doi:10.1371/journal.pone.0002455
    • Wood NI, Goodman AO, van der Burg JM, Gazeau V, Brundin P, Björkqvist M, Petersén A, Tabrizi SJ, Barker RA, Morton AJ (2008). Increased thirst and drinking in Huntington's disease and the R6/2 mouse.. Brain Res Bull, 76(1-2), 70 - 79. doi:10.1016/j.brainresbull.2007.12.007
    • Arnulf I, Nielsen J, Lohmann E, Schiefer J, Wild E, Jennum P, Konofal E, Walker M, Oudiette D, Tabrizi S, Durr A (2008). Rapid eye movement sleep disturbances in Huntington disease.. Arch Neurol, 65(4), 482 - 488. doi:10.1001/archneur.65.4.482
    • Wild EJ, Mudanohwo EE, Sweeney MG, Schneider SA, Beck J, Bhatia KP, Rossor MN, Davis MB, Tabrizi SJ (2008). Huntington's disease phenocopies are clinically and genetically heterogeneous.. Mov Disord, 23(5), 716 - 720. doi:10.1002/mds.21915

    2007

    • Wild EJ, Tabrizi SJ (2007). Huntington's disease phenocopy syndromes.. Curr Opin Neurol, 20(6), 681 - 687. doi:10.1097/WCO.0b013e3282f12074
    • Wild EJ, Tabrizi SJ (2007). The differential diagnosis of chorea.. Pract Neurol, 7(6), 360 - 373. doi:10.1136/pn.2007.134585
    • Kloppel S, Draganski B, Tabrizi SJ, Frackowiak RSJ (2007). White matter changes in the diagnosis of presymptomatic neurodegenerative diseases: The example of Huntington's disease.
    • Laureys S, Tabrizi S, Rees G, Omuro A, Delattre J-Y (2007). Editorial introductions. Current Opinion in Neurology, 20(6), - . doi:10.1097/WCO.0b013e3282f24d00
    • Wild EJ, Tabrizi SJ (2007). Genetic causes of dementia. Advances in Clinical Neuroscience and Rehabilitation, 7(2), 14 - 16.
    • Arnulf I, Nielsen J, Schiefer J, Wild E, Jennum P, Konofal E, Oudiette D, Tabrizi S, Durr A (2007). REM sleep disturbances in huntington disease.
    • Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, Piccini P (2007). Imaging microglial activation in Huntington's disease.. Brain Res Bull, 72(2-3), 148 - 151. doi:10.1016/j.brainresbull.2006.10.029
    • Kristiansen M, Deriziotis P, Dimcheff DE, Jackson GS, Ovaa H, Naumann H, Clarke AR, van Leeuwen FW, Menéndez-Benito V, Dantuma NP, Portis JL, Collinge J, Tabrizi SJ (2007). Disease-associated prion protein oligomers inhibit the 26S proteasome.. Mol Cell, 26(2), 175 - 188. doi:10.1016/j.molcel.2007.04.001
    • Zourlidou A, Gidalevitz T, Kristiansen M, Landles C, Woodman B, Wells DJ, Latchman DS, de Belleroche J, Tabrizi SJ, Morimoto RI, Bates GP (2007). Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation.. Hum Mol Genet, 16(9), 1078 - 1090. doi:10.1093/hmg/ddm057
    • Wild EJ, Petzold A, Keir G, Tabrizi SJ (2007). Plasma neurofilament heavy chain levels in Huntington's disease.. Neurosci Lett, 417(3), 231 - 233. doi:10.1016/j.neulet.2007.02.053
    • Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, Piccini P (2007). Microglial activation in presymptomatic Huntington's disease gene carriers.. Brain, 130(Pt 7), 1759 - 1766. doi:10.1093/brain/awm044
    • Dalrymple A, Wild EJ, Joubert R, Sathasivam K, Björkqvist M, Petersén A, Jackson GS, Isaacs JD, Kristiansen M, Bates GP, Leavitt BR, Keir G, Ward M, Tabrizi SJ (2007). Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates.. J Proteome Res, 6(7), 2833 - 2840. doi:10.1021/pr0700753
    • Runne H, Kuhn A, Wild EJ, Pratyaksha W, Kristiansen M, Isaacs JD, Régulier E, Delorenzi M, Tabrizi SJ, Luthi-Carter R (2007). Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood.. Proc Natl Acad Sci U S A, 104(36), 14424 - 14429. doi:10.1073/pnas.0703652104

    2006

    • Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, Piccini P (2006). Microglial activation in presymptomatic Huntington's disease gene carriers: A combined C-11-PK11195 and C-11-raclopride PET study.
    • Wild EJ, Tabrizi SJ (2006). Predict-HD and the future of therapeutic trials.. Lancet Neurol, 5(9), 724 - 725. doi:10.1016/S1474-4422(06)70531-2
    • Henley SM, Frost C, MacManus DG, Warner TT, Fox NC, Tabrizi SJ (2006). Increased rate of whole-brain atrophy over 6 months in early Huntington disease.. Neurology, 67(4), 694 - 696. doi:10.1212/01.wnl.0000230149.36635.c8
    • Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, Hooper C, Rijsdijk F, Tabrizi SJ, Banner S, Shaw CE, Foy C, Poppe M, Archer N, Hamilton G, Powell J, Brown RG, Sham P, Ward M, Lovestone S (2006). Proteome-based plasma biomarkers for Alzheimer's disease.. Brain, 129(Pt 11), 3042 - 3050. doi:10.1093/brain/awl279
    • Gandhi S, Wood-Kaczmar A, Jat P, Latchman DS, Tabrizi SJ, Wood NW (2006). Investigation of PINK1 dysfunction in Parkinson's disease.
    • Wood-Kaczmar A, Gandhi S, Jat P, Miljan EA, Sinden J, Keen GJ, Taylor J, Latchman DS, Wood NW, Tabrizi SJ (2006). Generation of a cellular model of PINK1 parkinsonism in primary human dopaminergic neurons.
    • Holmes E, Tsang TM, Tabrizi SJ (2006). The application of NMR-based metabonomics in neurological disorders.. NeuroRx, 3(3), 358 - 372. doi:10.1016/j.nurx.2006.05.004
    • Björkqvist M, Petersén A, Bacos K, Isaacs J, Norlén P, Gil J, Popovic N, Sundler F, Bates GP, Tabrizi SJ, Brundin P, Mulder H (2006). Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease.. Hum Mol Genet, 15(10), 1713 - 1721. doi:10.1093/hmg/ddl094
    • Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, Piccini P (2006). Microglial activation in presymptomatic Huntington's disease gene carriers: A combined C-11-PK11195 and C-11-raclopride PET study.
    • Golding CV, Danchaivijitr C, Hodgson TL, Tabrizi SJ, Kennard C (2006). Identification of an oculomotor biomarker of preclinical Huntington disease.. Neurology, 67(3), 485 - 487. doi:10.1212/01.wnl.0000218215.43328.88
    • Tsang TM, Woodman B, McLoughlin GA, Griffin JL, Tabrizi SJ, Bates GP, Holmes E (2006). Metabolic characterization of the R6/2 transgenic mouse model of Huntington's disease by high-resolution MAS 1H NMR spectroscopy.. J Proteome Res, 5(3), 483 - 492. doi:10.1021/pr050244o
    • Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, Piccini P (2006). Imaging activated microglia in presymptomatic Huntington's disease gene carriers: An 11C-PK11195 PET study.

    2005

    • Strand AD, Aragaki AK, Shaw D, Bird T, Holton J, Turner C, Tapscott SJ, Tabrizi SJ, Schapira AH, Kooperberg C, Olson JM (2005). Gene expression in Huntington's disease skeletal muscle: a potential biomarker.. Hum Mol Genet, 14(13), 1863 - 1876. doi:10.1093/hmg/ddi192
    • Hirsch N, Beckett A, Collinge J, Scaravilli F, Tabrizi S, Berry S (2005). Lymphocyte contamination of laryngoscope blades--a possible vector for transmission of variant Creutzfeldt-Jakob disease.. Anaesthesia, 60(7), 664 - 667. doi:10.1111/j.1365-2044.2005.04221.x
    • Allen DC, Loy CT, Wills AJ, Sawle GV, Tabrizi SJ (2005). Spinocerebellar ataxia type 17: Extension of phenotype with putaminal rim hyperintensity on magnetic resonance imaging.
    • Kristiansen M, Messenger MJ, Klöhn PC, Brandner S, Wadsworth JD, Collinge J, Tabrizi SJ (2005). Disease-related prion protein forms aggresomes in neuronal cells leading to caspase activation and apoptosis.. J Biol Chem, 280(46), 38851 - 38861. doi:10.1074/jbc.M506600200
    • Golding CVP, Danchaivijitr C, Hodgson TL, Tabrizi SJ, Kennard C (2005). Identification of an oculomotor biomarker of presymptomatic Huntington's disease.
    • Henley SM, Bates GP, Tabrizi SJ (2005). Biomarkers for neurodegenerative diseases.. Curr Opin Neurol, 18(6), 698 - 705.
    • Loy CT, Sweeney MG, Davis MB, Wills AJ, Sawle GV, Lees AJ, Tabrizi SJ (2005). Spinocerebellar ataxia type 17: extension of phenotype with putaminal rim hyperintensity on magnetic resonance imaging.. Mov Disord, 20(11), 1521 - 1523. doi:10.1002/mds.20529
    • Kristiansen M, Tabrizi SJ (2005). Protein aggregation, the ubiquitin-proteasome system and neurodegenerative diseases. Advances in Clinical Neuroscience and Rehabilitation, 5(2), 8 - 9.
    • Tabrizi SJ, Blamire AM, Manners DN, Rajagopalan B, Styles P, Schapira AH, Warner TT (2005). High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study.. Neurology, 64(9), 1655 - 1656. doi:10.1212/01.WNL.0000160388.96242.77
    • Henley SMD, Warrington EK, Frost C, MacManus DG, Warner TT, Fox NC, Tabrizi SJ (2005). Mri and cognitive changes detectable over 6 and 12 months in early Huntington's disease.
    • Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, Piccini P (2005). Microglial activation in presymptomatic Huntington's disease gene carriers: A C-11-PK11195 pet study.
    • Golding CVP, Danchaivijitr C, Hodgson TL, Tabrizi SJ, Kennard C (2005). Identification of an oculomotor biomarker of pre-symptomatic Huntington's disease.
    • Loy CT, Sweeney MG, Davis MB, Wills AJ, Sawle GV, Lees AJ, Tabrizi SJ (2005). Spinocerebellar ataxia type 17: Extension of phenotype with putaminal rim hyperintensity on magnetic resonance imaging. Movement Disorders, 20(11), 1521 - 1523. doi:10.1002/mds.20529
    • Batchelor T, Greenwood R, Tabrizi S (2005). Editorial introductions. Current Opinion in Neurology, 18(6), - .

    2004

    • Kristiansen M, Klohn PC, Messenger MJ, Sutton LM, Podesta JE, Collinge J, Tabrizi SJ (2004). Prion infection renders neuronal cells more susceptible to proteasome inhibition and apoptotic stimuli.
    • Tabrizi SJ, Blamire AM, Rajagopalan B, Manners D, Schapira AH, Warner TT (2004). High dose creatine therapy for Huntington's disease: Clinical and 31 Phosphorous magnetic resonance spectroscopy [(31p)MRS] findings in a 2-year study. doi:10.1002/mds.20169
    • Beck JA, Poulter M, Campbell TA, Uphill JB, Adamson G, Geddes JF, Revesz T, Davis MB, Wood NW, Collinge J, Tabrizi SJ (2004). Somatic and germline mosaicism in sporadic early-onset Alzheimer's disease.. Hum Mol Genet, 13(12), 1219 - 1224. doi:10.1093/hmg/ddh134
    • Orth M, Tabrizi SJ, Tomlinson C, Messmer K, Korlipara LV, Schapira AH, Cooper JM (2004). G209A mutant alpha synuclein expression specifically enhances dopamine induced oxidative damage.. Neurochem Int, 45(5), 669 - 676. doi:10.1016/j.neuint.2004.03.029
    • Tabrizi SJ, Beck JA, Poulter M, Campbell T, Uphill JB, Adamson G, Geddes JF, Revesz T, Davis M, Wood N, Collinge J (2004). Somatic mosaicism in sporadic early-onset Alzheimer's disease.
    • Beck JA, Poulter M, Campbell T, Uphill JB, Adamson G, Geddes JF, Revesz T, Davis M, Wood NW, Collinge J, Tabrizi SJ (2004). Nuclear somatic mosaicism in sporadic early-onset Alzheimer's disease.
    • Henley SM, Warrington EK, Warner TT, Stevens JM, Ashburner J, Rossor MN, Fox NC, Tabrizi SJ (2004). Correlation between patterns of atrophy and psychomotor task performance in early Huntington's disease.

    2003

    • Tabrizi SJ, Elliott CL, Weissmann C (2003). Ethical issues in human prion diseases.. Br Med Bull, 66, 305 - 316.
    • Tabrizi SJ, Collinge J (2003). Transmissable spongiform encephalopathies of humans and animals. In Cohen J, Powderly WG (Ed.), Infectious diseases (pp. 297 - 305). : Mosby.
    • Orth M, Tabrizi SJ (2003). Models of Parkinson's disease.. Mov Disord, 18(7), 729 - 737. doi:10.1002/mds.10447
    • Orth M, Tabrizi SJ, Schapira AH, Cooper JM (2003). Alpha-synuclein expression in HEK293 cells enhances the mitochondrial sensitivity to rotenone.. Neurosci Lett, 351(1), 29 - 32.
    • McKintosh E, Tabrizi SJ, Collinge J (2003). Prion diseases.. J Neurovirol, 9(2), 183 - 193. doi:10.1080/13550280390194082
    • Ahmad-Annuar A, Tabrizi SJ, Fisher EM (2003). Mouse models as a tool for understanding neurodegenerative diseases.. Curr Opin Neurol, 16(4), 451 - 458. doi:10.1097/01.wco.0000084221.82329.29
    • Behrendt GC, Tabrizi SJ, Turner C, Levine TS, Sheppard MN (2003). Idiopathic intimal hyperplasia of small arteries and arterioles affecting intestines and myocardium.. Cardiovasc Pathol, 12(1), 32 - 35.
    • Tabrizi SJ, Blamire AM, Manners DN, Rajagopalan B, Styles P, Schapira AH, Warner TT (2003). Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study.. Neurology, 61(1), 141 - 142.

    2002

    • Tabrizi SJ, Schapira AHV (2002). Mitochondrial abnormalities in neurodegenerative disorders. In Schapira AHV, DiMauro S (Ed.), Mitochondrial disorders in neurology 2 (pp. 143 - 174). : Butterworth-Heinemann.
    • Tabrizi SJ, Rajagopalan B, Styles P, Manners D, Schapira AH, Warner TT (2002). Creatine therapy for Huntington's disease (HD): Clinical and-(31)phosphorous magnetic resonance spectroscopy (P-31 MRS) findings in a one year pilot.
    • Hafezparast M, Ahmad-Annuar A, Wood NW, Tabrizi SJ, Fisher EM (2002). Mouse models for neurological disease.. Lancet Neurol, 1(4), 215 - 224.
    • Tabrizi SJ, Schapira AHV (2002). Chapter 5 Mitochondrial Abnormalities in Neurodegenerative Disorders. Blue Books of Practical Neurology, 26(C), 143 - 174. doi:10.1016/S1877-3419(09)70064-9

    2000

    • Orth M, Tabrizi SJ, Schapira AH (2000). Sporadic inclusion body myositis not linked to prion protein codon 129 methionine homozygosity.. Neurology, 55(8), 1235 - .
    • Tabrizi SJ, Orth M, Wilkinson JM, Taanman JW, Warner TT, Cooper JM, Schapira AH (2000). Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity.. Hum Mol Genet, 9(18), 2683 - 2689.
    • Tabrizi SJ, Workman J, Hart PE, Mangiarini L, Mahal A, Bates G, Cooper JM, Schapira AH (2000). Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse.. Ann Neurol, 47(1), 80 - 86.

    1999

    • Schapira AHV (1999). Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Parkinsonism and Related Disorders, 5, 139 - 143.
    • Tabrizi SJ, Schapira AH (1999). Secondary abnormalities of mitochondrial DNA associated with neurodegeneration.. Biochem Soc Symp, 66, 99 - 110.
    • Tabrizi SJ, Cleeter MW, Xuereb J, Taanman JW, Cooper JM, Schapira AH (1999). Biochemical abnormalities and excitotoxicity in Huntington's disease brain.. Ann Neurol, 45(1), 25 - 32.

    1998

    • Tabrizi SJ, Schapira AHV (1998). Primary and secondary deficiencies of the mitochondrial respiratory chain. NEUROLOGIST, 4(4), 169 - 179.
    • Tabrizi SJ, Cooper JM, Schapira AH (1998). Mitochondrial DNA in focal dystonia: a cybrid analysis.. Ann Neurol, 44(2), 258 - 261. doi:10.1002/ana.410440218
    • Schapira AH, Gu M, Taanman JW, Tabrizi SJ, Seaton T, Cleeter M, Cooper JM (1998). Mitochondria in the etiology and pathogenesis of Parkinson's disease.. Ann Neurol, 44(3 Suppl 1), S89 - S98.
    • Lodi R, Taylor DJ, Tabrizi SJ, Hilton-Jones D, Squier MV, Seller A, Styles P, Schapira AH (1998). Normal in vivo skeletal muscle oxidative metabolism in sporadic inclusion body myositis assessed by 31P-magnetic resonance spectroscopy.. Brain, 121 ( Pt 11), 2119 - 2126.
    • Cock HR, Tabrizi SJ, Cooper JM, Schapira AH (1998). The influence of nuclear background on the biochemical expression of 3460 Leber's hereditary optic neuropathy.. Ann Neurol, 44(2), 187 - 193. doi:10.1002/ana.410440208

    1997

    • Lodi R, Taylor DJ, Tabrizi SJ, Kumar S, Sweeney M, Wood NW, Styles P, Radda GK, Schapira AH (1997). In vivo skeletal muscle mitochondrial function in Leber's hereditary optic neuropathy assessed by 31P magnetic resonance spectroscopy.. Ann Neurol, 42(4), 573 - 579. doi:10.1002/ana.410420407
    • Tabrizi SJ, Cooper JM, Xuereb JH, Schapira AHV (1997). Mechanisms involved in the pathogenesis of Huntington's disease. ANN NEUROL, 42(3), T202 - T202.

    1996

    • Tabrizi SJ, Scaravilli F, Howard RS, Collinge J, Rossor M (1996). Creutzfeldt-Jakob disease in a young woman. LANCET, 347(9006), 945 - 948.

    1994

    • Tabrizi SJ, Scott J, Pusey CD, Lacey S, Davies KAA, Rees AJ, Beynon H, Oakley C (1994). Nocardia pericarditis: A rare opportunistic infection. British Medical Journal, 309(6967), 1495 - 1497.
    • TABRIZI SJ, SCOTT J, PUSEY CD, LACEY S, DAVIES RAA, REES AJ, BEYNON H, OAKLEY C, WHYTE M (1994). GRAND ROUNDS - HAMMERSMITH-HOSPITAL - NOCARDIA-PERICARDITIS - A RARE OPPORTUNISTIC INFECTION.

    1990

    • HARDY J, GOATE A (1990). PRION DISEASE. In (Ed.), (pp. 370 - 370). : .

    • Tabrizi SJ (). Huntington's Disease and other Choreas. In (Ed.), Neurodegeneration (pp. - ). : Blackwell Publishing Ltd.